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Abstract
Background: Lynch syndrome (LS) is a hereditary condition that increases the risk for endometrial and other
cancers. The identification of endometrial cancer (EC) patients with LS has the potential to influence life-saving
interventions. We aimed to study the prevalence of LS among EC patients in our population.
Methods: Universal screening for LS was applied for a consecutive series EC. Tumor testing using microsatellite
instability (MSI), immunohistochemistry (IHC) for mismatch-repair (MMR) protein expression and MLH1-methylation
analysis, when required, was used to select LS-suspicious cases. Sequencing of corresponding MMR genes was
performed.
Results: One hundred and seventy-three EC (average age, 63 years) were screened. Sixty-one patients (35%) had
abnormal IHC or MSI results. After MLH1 methylation analysis, 27 cases were considered suspicious of LS. From
these, 22 were contacted and referred for genetic counseling. Nineteen pursued genetic testing and eight were
diagnosed of LS. Mutations were more frequent in younger patients (<50 yrs). Three cases had either intact IHC or
MSS and reinforce the need of implement the EC screening with both techniques.
Conclusion: The prevalence of LS among EC patients was 4.6% (8/173); with a predictive frequency of 6.6% in the
Spanish population. Universal screening of EC for LS is recommended.
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Introduction
Identification of hereditary forms of neoplasias among cancer
patients is crucial for better management and prevention of
other syndrome-associated malignancies for the patients and
their families [1]. The estimated incidence and mortality count
of endometrial cancer (EC) in Europe in 2012 were 58,300 and
24,400, respectively. EC accounts for approximately 4% of all
cancers in women [2]. The incidence is increasing and
approximately 5% of cases are thought to result from a genetic
predisposition [3].
Lynch syndrome (LS) is an autosomal dominant condition
caused by a mutation in the mismatch repair (MMR) genes,
MLH1, MSH2, MSH6 and PMS2 [4]. Mutation carriers are at
risk of early onset colorectal cancer (CRC), EC and a spectrum
of other tumors such as ovarian, gastric, small bowel,
pancreatic, hepatobiliary, brain and urothelial neoplasms [5].
The cumulative lifetime risk of EC for female carriers of an
MMR mutation is 50–60% and exceeds the risk of a CRC [6].
The identification of patients with EC and LS has the
potential to influence life-saving interventions through
personalized counseling and intensive cancer surveillance with
early detection, screening and prevention of other LS-
associated cancers. Genetic testing is now an accepted part of
the management of patients with such cancers. The Mallorca
group [7] recommended testing all cases of CRC (or individuals
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with a CRC aged <70 years) and all cases of EC (or individuals
with an EC aged <70 years) by immunohistochemistry (IHC) for
MMR genes or chromosomal microsatellite instability (MSI).
The prevalence of LS among unselected cases of CRC has
been studied well. The results indicate that 0.7% to 3.6% of all
such cases might be caused by germline mutations in MMR
genes [8–12]. On the contrary, research on LS-related ECs is
still evolving and little is known about the genetic components
among patients with EC. Current data on the prevalence of LS
among unselected cases of EC in North America range
between 1.8% and 4.5% [13–15]. Significant differences in the
prevalence of hereditary syndromes are frequently observed
among different populations [12]. Here we report on the
prevalence of LS in a consecutive series of patients with EC
from the Spanish population.
Materials and Methods
Ethical issues
Tumor tissue and blood samples from patients with EC were
obtained from the Biobank of the Alicante University Hospital
(HGUA) in Spain. Written consent to be included in the Biobank
was obtained from each patient. The Ethics Committee of
HGUA approved the study.
Subjects
One hundred seventy-three consecutive patients with newly
diagnosed ECs were included in this study. They were
diagnosed and treated at the HGUA from 2004–2009. For each
case, all available hematoxylin–eosin slides were reviewed and
classified using the 2003 World Health Organization criteria
[16]. Additional histopathology features recorded were the
presence of lymphovascular invasion (LVI), tumor-infiltrating
lymphocytes (TILs), myometrial invasion, and grade and stage
according to the International Federation of Obstetrics and
Gynaecology (FIGO). The adenocarcinomas were classified
into endometrioid (type I) and special (type II) according to
Peiró et al 2013 [17]. A familial history of cancer was evaluated
according to the revised Bethesda guidelines (rBG) and
Amsterdam II criteria (AmII) [18].
Immunohistochemistry of MMR proteins
IHC analysis of the expression of the MLH1, MSH2, MSH6
and PMS2 proteins was performed using a tissue microarray
(TMA). Tissue cylinders of 1 mm diameter were punched out
from selected areas and incorporated into a recipient paraffin
block using a TMA instrument (MTA-1,Beecher Instrument,
Wisconsin USA). Four-millimeter-thick sections were prepared
from the TMA samples. The slides were placed on a
Autostainer Link48 (Dako, Denmark) and incubated for 30 min
at room temperature with primary antibodies to MLH1 (clone
G168–15; 1:30; BD Biosciences Pharmingen, Franklin Lakes,
NJ, USA), MSH2 (clone 44; dilution 1:100; BD Transduction
Laboratories, San Diego, CA, USA), MSH6 (clone FE11;
dilution 1:30; Calbiochem, Merck Millipore, Billerica, MA, USA)
and PMS2 (clone A16–4; dilution 1:100; BD Biosciences
Pharmingen). Antibodies were detected using the EnVision
technique (Dako-Biotech). Tumor cells were judged as
negative for protein expression only if they lacked IHC staining
in a sample in which normal endometrial cells and stromal cells
were stained concurrently. Results were considered unreliable
in those cases where no immunostaining of normal tissue could
be demonstrated. The processed IHC slides were blinded
evaluated by two pathologists (CE and CA) [19].
DNA extraction
Genomic DNA was isolated from paraffin wax-embedded
tumor tissues. Two 1 mm tissue cylinders were punched out
from the tumor areas selected previously. DNA from peripheral
blood leukocytes or from paraffin wax-embedded nontumorous
endometrium tissue was also extracted from those cases
where LS was suspected. A DNeasy Blood & Tissue kit and
QiaCube (Qiagen, Valencia, CA, USA) automatic system was
used to isolate DNA, according to the manufacturer’s protocol.
Microsatellite analysis and MMR status
MSI status was analyzed using multiplexed polymerase
chain reaction (PCR) patterns at the monomorphic repetitive
markers: BAT26, BAT25, NR21, NR24 and NR27 [20].
Amplicon detection and analysis were performed using an ABI
Prism 3130 Genetic Analyzer, and Genotyper software (Life
Technologies, Carlsbad, CA, USA), respectively. A diagnosis of
MSI was considered positive when two or more markers
showed an altered pattern. Tumors with MSI and/or loss of
expression of any of the MMR proteins were considered as
MMR-deficient. Tumors with absence of MSI and preserved
MMR protein expression were considered as MMR-positive
tumors.
MLH1 promoter hypermethylation analysis
Cases with loss of MLH1 expression were tested for MLH1
methylation in the tumor DNA. Any cases with such methylation
were then analyzed for MLH1 methylation in DNA from blood
cells to identify suspected constitutional MLH1 epimutations
(Figure 1). We used the methylation-specific multiplex ligation-
dependent probe-amplification technique (MS-MLPA Kit
ME011; MRC-Holland, Amsterdam, The Netherlands) to study
the methylation status of MLH1, according to the
manufacturer’s protocols. The target regions for MLH1 gene
silencing by hypermethylation are located in the C and D
regions of the MLH1 promoter (from nucleotide positions -248
to -178 and -109 to +15) [21], which were tested using the
probes MLH1-3 and -4, respectively. The mean results for
these two probes were calculated to obtain the methylation
ratio. The threshold for methylated versus unmethylated status
was set at 15%, based on a previous study of MLH1 gene
silencing [22]. MS-MPLA fragments were analyzed using an
ABI Prism 3130 Genetic Analyzer, and Genotyper software
(Life Technologies).
Germline mutations
Patients in whom we suspected LS and were candidates for
genetic testing were referred to the Genetic Counseling division
in our unit. Suspicion of LS was based on MMR status (IHC
Lynch Syndrome in Endometrial Cancer Patients
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and MSI results) and the MLH1 methylated status, according to
our decision tree algorithm (Figure 1). MLH1 gene testing was
performed in cases where tumors showed loss of protein
expression and unmethylated MLH1. MSH2 mutational
analysis was performed in those cases with MSH2-negative
staining tumors. MSH6 germline analysis was done in patients
with a lack of MSH6 protein expression but with normal
expression of MSH2. Tumors with a combined lack of MSH2
and MSH6 proteins with an undetected mutation in MSH2 were
also tested for MSH6 genetic alterations. Cases tested for
MSH2 and MSH6 with no mutation detected were also
analyzed for large rearrangements at the EPCAM locus.
Genetic testing for PMS2 was performed only in those patients
with tumors showing loss of expression of PMS2 and normal
expression of MLH1.
Germline mutation studies were performed on genomic DNA
isolated from peripheral blood leucocytes or from nontumorous
endometrial tissue. Detection of point mutations was conducted
using PCR and direct sequencing of the whole coding
sequence and intron–exon boundaries for each gene [12].
Large rearrangements (deletions and/or insertions) for MMR
genes were screened by MLPA according to the manufacturer
protocols (Salsa MLPA kits P003, P072 and P008; MRC-
Holland). Confirmation testing was also performed using MLPA
with a different combination of probes (Salsa MLPA kit P248;
MRC-Holland). Analysis of deletions at the EPCAM locus was
also done using MLPA (Salsa MLPA kit P072-B1; MRC-
Holland). The interpretation of genetic analysis results was
based on the American College of Medical Genetics (ACMG)
Recommendations for Standards for Interpretation of
Sequence Variations [23], the InSiGHT database [24], and the
references therein were reviewed for classifying genetic
variants.
Data management and statistical analysis
Analysis was carried out using R software, version 2.15.2
(The R Project for Statistical Computing. Available: http://
www.r-project.org. Accessed 2013 Oct 21) and the Epicalc
epidemiological analysis package [25]. Relevant measures of
central tendency (means, medians and interquartile ranges for
Figure 1.  Decision–support flow diagram for patients with Lynch syndrome: genetic diagnosis strategy.  
doi: 10.1371/journal.pone.0079737.g001
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skewed data) were used to explore the data. The chi-squared
test was used to compare qualitative variables. Student’s t test
was used to compare normally distributed continuous
variables. Significance was set at p < 0.05 and results are
presented as the odds ratio (OR) and 95% confidence interval
(CI).
Results
A total of 173 unselected patients with ECs was included.
The mean age at diagnosis was 63.3 years (range 29–90). All
patients underwent biopsy or hysterectomy and paraffin wax-
embedded tissues were available for IHC and molecular
testing. The clinical and histopathology characteristics of the
tumors are shown in Table 1. Most tumors were of
endometrioid histology (79.2%) and FIGO grade 1 (54.9%). No
myometrial invasion was found in 10.3% of patients (15/146).
About 63.7% of cases had myometrial invasion ≤50% (96/146)
and 26% (38/146) had myometrial invasion >50%. TILs were
present in 29.4% of tumors (47/160) and 17.9% of tumors had
LVI (24/134). Twenty-six patients (17.1%) had synchronous
endometrial and ovarian cancers.
Familial histories of cancer, histopathology and molecular
characteristics regarding LS are shown in Table 2. Eight
patients (4.6%) had a history of colorectal lesions and 10
(5.8%) had a history of breast cancer and other neoplasias. A
familial history of cancer was available in 87 cases: 42 (48.3%)
fulfilled the rBG criteria and four (4.6%) fulfilled the AmII
criteria. Family history of cancer from the remaining 86 cases
was unavailable because unconfirmed family history, were lost
to follow-up or deceased.
We found an altered MMR picture (loss of MMR protein
expression and/or MSI) in 61 patients (35.3%). Loss of MLH1
expression was found in 44 patients (25.4%). From these, 34
(77.3%) showed MLH1 hypermethylation in the tumor.
Thereafter, MLH1 hypermethylation analysis was done in nine
of these cases where DNA from blood cells was available, but
gave negative results in all of them. Thus, all tumors with MLH1
hypermethylation were considered sporadic ECs.
Loss of MSH2/MSH6 was detected in five patients (2.9%)
while loss of only MSH6, or only PMS2 protein expression, was
observed in eight (4.6%). One case, with both losses of MSH6
and PMS2, was found (Table S1 in File S1). All these cases,
together with another 10 cases with loss of MLH1 expression
and absence of MLH1 methylation were considered suspicious
of LS and suitable for genetic testing.
A significant association was found between the IHC and
MSI results (p < 0.0001) showing concordance in 90.2% of
cases (156/173). Discordances between IHC and MSI were
found in 17 cases (9.8%). Loss of expression of MMR proteins
and MSS was found in 14 cases. Normal expression of MMR
proteins and MSI were found in three cases.
We did not have evidence for a sporadic origin of these
tumors so they were also considered as suspected LS. Finally,
a total of 27 (15.6%) cases were included in the genetic
analysis for germline mutation screening.
Comparative analysis among the suspected cases of LS and
cases with MMR proficient ECs showed that the suspected
hereditary condition was more frequently found in women
younger than 50 years (OR 2.84; 95% CI 1.04–7.77). No
significant differences were found in any other clinical or
pathological variables (Table 3). Similar results were obtained
when we compared patients showing abnormal MMR with
those with retained MMR function (Table S2 in File S1), with
the exception of TIL and LIV, which was strongly associated
with abnormal MMR tumors (OR 5.88; 95% CI 2.80–12.31 and
OR 3.03; 95% CI 1.22–7.56, respectively).
Germline mutation analyses were performed for 19 patients
of the suspected LS group (19/27, 70.4%). Genetic test results
for the remaining eight patients were unavailable because they
rejected the testing (3/27, 11.1%), were lost to follow-up (3/27,
11.1%) or deceased (2/27, 7.4%).
We found eight patients with pathogenic mutations (8/19,
42.1%) representing 4.6% of the whole series; one in MLH1,
three in MSH2, three in MSH6 and one in PMS2 genes (Table
4). The mean age of these patients was 49 years, significantly
Table 1. Clinical and pathologic characteristics.
Variable N [ ]
Number of patients 173  
Mean age (SD) and range in years 63.27(+/- 12.37) 29-90
 N %
Stage at initial diagnosis 158  
I 119 75.3
II 6 3.8
III 31 19.6
IV 2 1.3
Histology 173  
Endometroid 137 79.2
Poorly Diferenciated 8 4.6
Papilary Serous 13 7.5
Clear Cell 11 6.4
Mülerian Mixet Tumor 4 2.3
Grade (FIGO) 173  
1 95 54.9
2 29 16.8
3 49 28.3
Myometrial invasion 146  
None 15 10.3
≤50% 93 63.7
>50% 38 26.0
Tumor infiltrating lymphocytes 160  
No 113 70.6
Yes 47 29.4
Lymphovascular invasion 134  
No 110 82.1
Yes 24 17.9
Low Uterin Segment 173  
No 157 90.8
Yes 16 9.2
Synchronous ovarian cancer 152  
No 126 82.9
Yes 26 17.1
doi: 10.1371/journal.pone.0079737.t001
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lower than in the non-LS EC group (Table S3 in File S1).
Twenty-five percent of them did not fulfill the rBth criteria and
another 25% showed negative MSI (with isolated loss of
protein expression in MSH6 and PMS2) (Table S4 in File S1).
Two patients had synchronous ovarian cancers and one had a
synchronous colon cancer (Table 5). The presence of
synchronous ovarian cancer and tumor infiltrating lymphocytes
was associated to confirmed LS cases when compared to non-
LS EC (Table S3 in File S1).
Three of the mutations (37.5%) were large deletions (two in
MSH2 and one in PMS2), another three (37.5%) were
nonsense mutations (all in the MSH6 gene) and two (25%)
were frameshift mutations (one insertion in MLH1 and one
deletion in MSH2). Another two patients showed genetic
missense variants of unknown clinical significance, both in
MSH6 (c.116GA; p.Gly39Glu; and c.1109TC; p.Leu370Ser).
Prediction using Polyphen-2 (http://genetics.bwh.harvard.edu/
pph2/) classified both variants as probably pathogenic. In
addition, both tumors showed loss of expression of MSH6 with
conserved expression of MSH2, and absence of MSI.
In the association study comparing mutated with nonmutated
cases, only age was found to be significant. Mutations were
more frequently found in patients with EC diagnosed before 50
years of age (OR 16.67; 95% CI 1.01–588.03; p = 0.048). No
significant associations were found regarding rBG criteria, IHC,
MSI status, histopathology or the presence of synchronous
tumors.
Table 2. Features related to Lynch syndrome.
Variable N %
Lynch syndrome criteria 87  
Reviewed Bethesda criteria 38 43.68
Amsterdam II criteria 4 4.60
No Fullfill 45 51.72
Personal History of Colorectal Lesions 8  
Colon cancer 6 3.47*
Polyps 2 1.16*
Personal History Others Tumors 15  
Breast cancer 10 5.78*
Lung cancer 2 1.16*
Pleura 1 0.58*
Thyrod cancer (Medular) 1 0.58*
Urothelial Cancer 1 0.58*
IHC protein expression: Loss of MLH1/MSH2/MSH6/PMS2 173  
No 115 66.47
Yes 58 33.53
MSI Status 173  
MSS 126 72.83
MSI 47 27.17
Mismatch Repair status 173  
Proficient 112 64.74
Deficient 61 35.26
*. Calculated from whole series (n=173).
doi: 10.1371/journal.pone.0079737.t002
Discussion
A small proportion of ECs might be the result of a genetic
risk condition [3]. LS is the main syndrome involved in such
cases [5,6], although the existence of a familial site-specific EC
genetic entity separate from LS has been sugested [26]. The
current data about the prevalence of LS among patients with
Table 3. Comparative analysis of patients with suspected
Lynch syndrome and MMR proficient endometrial cancers.
 Suspected LS MMR proficient  p
Number of patients 27  146    
Mean age (SD) 57.70 (12.45) 64.31 (12.12)  0.01
 N % N % OR (IC 95%) p
Age       
<50 yrs 7 25.93 16 10.96 2.84 (1.04-7.77) 0.04
≥50 yrs 20 74.07 130 89.04   
Histology       
Endometroid (type I) 22 81.48 123 84.25 0.82 (0.28-2.39) 0.72
Special (type II) 5 18.52 23 15.75   
Grade (FIGO)       
High 9 33.33 40 27.40 1.32 (0.5-3.19) 0.53
Low 18 66.67 106 72.60   
Myometrial
invasion       
(n=146)       
>50% 6 25.00 32 26.23 0.93 (0.34-2.57) 0.90
≤50% 18 75.00 90 73.77   
Tumor infiltrating
lymphocytes      
(n=160)       
Yes 9 33.33 38 28.57 1.25 (0.52-3.03) 0.62
No 18 66.67 95 71.43   
Lymphovascular invasion      
(n=134)       
Yes 7 30.43 17 15.32 2.42 (0.87-6.76) 0.09
No 16 69.57 94 84.68   
Low Uterin
Segment       
Yes 4 14.81 12 8.22 1.94 (0.57-6.54) 0.28
No 23 85.19 134 91.78   
Synchronous ovarian
cancer      
(n=152)       
Yes 5 18.52 22 17.60 1.06 (0.36-3.11) 0.91
No 22 81.48 103 82.40   
Reviewed Bethesda criteria      
(n=86)       
Fullfill 14 60.87 28 44.44 1.94 (0.73-5.14) 0.18
No Fullfill 9 39.13 35 55.56   
Amsterdam II
criteria       
(n=17)       
Fullfill 3 33.33 1 12.50 3.50 (0.28-43.16) 0.31
No Fullfill 6 66.67 7 87.50   
doi: 10.1371/journal.pone.0079737.t003
Lynch Syndrome in Endometrial Cancer Patients
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EC is limited and restricted to populations from the United
States [13–15]. Differences in the prevalence of genetic
diseases are frequently observed between different
populations, especially for syndromes where the penetrance is
incomplete and other genetic and environmental factors might
act as penetrance modifiers.
We aimed to determine the prevalence of LS among patients
with ECs in our Spanish population, to establish proper
screening strategies for identifying individuals with genetic
predispositions to other tumors; consequently, to identify family
members at risk and establish personalized follow-up
recommendations.
We used a prevalence study using established
recommendations and consensus algorithms for screening and
mutation analysis [7]. To maximize our mutation detection
sensitivity, no limit on age at diagnosis was considered. IHC
and MSI analysis were performed for all tumors. MLH1
methylation was tested in tumors and also in blood when
required and mutational analysis was done for the four
common MMR and EPCAM genes.
Our IHC and MSI screening detected 35.3% (61/173) of
tumors with deficient MMR, which is higher than those 22.8%
(124/543) and 25.3% (62/245) found by Hampel et al,2006 and
Moline et al, 2013, respectively. We found normal IHC
expression of MMR proteins together with MSI in 3/61 cases
(4.9%). Similar results were obtained by Hampel et al. 2006
(6.3%, 6/96) [13]. Moreover, we found that about 23% (14/61)
Table 4. IHC patterns of suspected Lynch syndrome.
IHC pattern Suspected Lynch
Germline mutation / analyzed
cases
Loss of MLH1 no Methylated 10 1/6
Loss of MSH2/MSH6 5 3/4
Loss of MSH6 7 2/5
Loss of PMS2 1 1/1
Loss of MSH6/PMS2 1 0/1
MSI + normal IHC 3 1/2
TOTAL 27 8/19
doi: 10.1371/journal.pone.0079737.t004
of tumors had loss of expression of an MMR protein and MSI.
The expected percentage of loss of expression and MSI in the
Hampel (2006) study [13] would be about 15%. Interestingly,
we found that two unrelated patients with these apparent
discordances had the same mutation at MSH6 (c.1367GA;
p.Trp456*), suggesting that in some circumstances the nature
of the second hit could be determinant for the tumor’s IHC and
MSI characteristics (Table 5). Our data shows that in patients
with EC, up to 27.9% of cases with MMR deficiency might have
either normal IHC results or MSI and reinforces the need for
implementing screening with both techniques.
Comparative analysis of our MMR deficient versus positive
cases did show a significant association with LVI and TILs, as
described elsewhere [27,28]. However, no association was
found between age at diagnosis and the rBG or AmII criteria
(Table S2 in File S1). These results could be explained by the
frequent occurrence of somatic MMR deficiency in ECs [13].
MLH1 methylation and BRAF mutation analyses allow one to
identify sporadic forms of CRC among MMR-deficient tumors.
We found no case mutated in BRAF (data not shown). Thus,
this gene does not have a major role in EC and should not be
included in the screening algorithm [15]. In contrast, MLH1
promoter methylation was present in the majority of tumors
along with the loss of expression of MLH1 (77.3%, 34/44). This
proportion was significantly lower than the 94% (79/84) found
by Hampel et al, 2006 [13]. Differences among the two cohorts
and different methodologies for the methylation analysis (MS-
MLPA vs MS-PCR) might have contributed to this disparity.
Constitutional epimutations to the MLH1 gene in cases of EC
are very rare [29]. None of the nine cases analyzed with tumor
methylation had MLH1 methylation in blood DNA. Thus, a
tumor with MLH1 methylation is unlikely to be LS-associated. In
contrast, a tumor that shows loss of MLH1 and PMS2 by IHC,
with no evidence of methylation, is likely to be associated with
LS [1].
After the initial screening, we selected 27 patients (15.61%)
suspected of LS. The mean age in this group was 57.7 years
and patients younger than 50 were more frequent (Table 3). No
other pathological or clinical characteristic was found to be
associated with suspected LS cases. Currently, there have
been attempts to identify pathological factors in LS-associated
EC. Some authors have identified the tumor localization
reporting a significantly higher prevalence of lower uterine
Table 5. Characteristics of patients with germline mutation.
Case rBG Age MSI status IHC loss Gene Nucleotide nomenclature Protein nomenclature Synchronous tumor/lesions
End131 Yes 41 MSI MLH1/PMS2 MLH1 c.2154_2157insAACA# p.His718Glnfs*5 Colonic Polyp
End111 Yes 45 MSI MSH2/MSH6 MSH2 c.1-?_645+?del Deletion of exon 1-3 p? Colon cancer
End091 Yes 40 MSI MSH2/MSH6 MSH2 c.1226_1227delAG p.Gln409Argfs*7 Ovarian cancer
End003 Yes 60 MSI MSH2/MSH6 MSH2 c.1387-?_1661del Deletion of exon 9-10 p? None
End014 No 61 MSI MSH6 MSH6 c.2731CT p.Arg911* None
End088 Yes 45 MSS MSH6 MSH6 c.1367GA# p.Trp456* Ovarian cancer
End137 No 56 MSI No loss MSH6 c.1367GA# p.Trp456* None
End034 Yes 44 MSS PMS2 PMS2 c.538-?_705+?del Deletion of exon 6# p? None
#. Not described at InSiGHT database.
doi: 10.1371/journal.pone.0079737.t005
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segment tumors in patients with LS [30,31]. Westin et al.
concluded that screening for LS should be considered in cases
with ECs originating in the lower uterine segment [30]. This
location can be a source of diagnostic consternation because it
can host both endometrial and endocervical carcinomas,
resulting in tumor misclassification [32].
Mutations were found in eight patients (42.1%) with a mean
age of 49 years. MSH6 and MSH2 were mutated in six cases
(Table 5). Two cases with mutations MSH6 (ages 56 and 61
years) did not fulfill the rBG criteria and no other synchronous
tumor was present at diagnosis. Thus, about 25% of patients
with EC associated with LS might appear to have sporadic
tumors and go undiagnosed when the rBG criteria are used to
test a suspicion of LS. LS-related ECs commonly result from
mutations in MSH6 and occur at later ages than do mutations
in MLH1 and MSH2 [33,34]. For patients with LS-related ECs,
the risk of developing a second cancer following the initial EC
diagnosis is estimated at 25% in 10 years and 50% at 15 years
[35,36]. The 20-year cumulative risk of cancer after endometrial
cancer has been recently reported with 48% risk for CRC; 11%
for cancer of the kidney, renal pelvis, or ureter; 9% for urinary
bladder cancer; and 11% for breast cancer [37]. Among
patients with LS, 50% of the ECs present before a diagnosis of
CRC, if the diagnoses are not synchronous. Therefore, EC can
serve as a ‘sentinel’ cancer for patients and potentially for their
family members [38].
In our study, mutations were found more frequently in
patients with ECs diagnosed before 50 years of age and no
association was found regarding the rBG criteria, IHC or MSI
status, histopathology and the presence of synchronous
tumors. However, it is possible that the limited sample size
could be hiding any other association.
There are several possibilities to explain those cases with
undetected germline mutations. First, presence of mutations at
untested regulatory regions of the analyzed genes; second, an
MMR deficiency caused by somatic biallelic inactivation; third,
genetic mosaicism; fourth, germline mutations in other genes
directly or indirectly involved with MMR function, such as
SETD2 [39], POLE and POLD1 [40], and finally other unknown
genetic or epigenetic mechanisms (Figure 1).
Many institutions and policy groups are considering whether
to implement screening for patients with LS among patients
with ECs. Different screening strategies for women with EC
have been shown to be cost effective [41,42]. IHC triage of all
cases of EC can identify most mutation carriers but at
considerable cost. The inclusion of at least one first-degree
relative with an LS-associated cancer at any age might prove
cost effective [42]. Nevertheless, it is important to stress that
multiple local factors might interfere in the efficiency of any
process. New approaches for making the universal screening
of patients with EC by IHC more cost effective are in progress.
Recent data suggest that a two-antibody panel testing for
PMS2 and MSH6 is as effective as the four-antibody panel for
detecting MMR abnormalities [43,44]. We observed that to
increase sensibility in LS diagnosis an analysis of MSI
combined with IHC should be considered because about 5%
(3/61) of patients with suspected LS and one-eighth of
confirmed LS cases in our study had MSI with intact IHC.
The prevalence of LS we found among patients with EC was
4.6% (8/173); with a predictive frequency of 6.6% for the
Spanish population. This prediction was made extrapolating the
found frequency of mutated cases and considering the possible
absence of lost cases. Is important to note that the present
work is a prevalence study conducted in a single hospital from
Spain, therefore extrapolation of data to the whole Spanish
population may be biased.
Previous studies from North American populations showed
prevalence rates ranging from 1.8% to 4.5% [13–15]. In our
population, we found that the prevalence of LS among patients
with EC is sixfold higher than the prevalence of LS among
patients with CRCs (4.6% vs 0.7%) [12].
In conclusion, we found a high prevalence of LS among
patients with ECs (4.6–6.6%). Unlike CRC, only the patient’s
age at diagnosis was found to be associated with LS.
Consistent with these results, we consider that universal
screening of all patients with ECs by IHC, MSI and MLH1
methylation analysis should be recommended.
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